 |
|
Plaque Radiotherapy for Uveal Melanoma
Long-term Visual Outcome in 1106 Consecutive Patients
Carol L. Shields, MD;
Jerry A. Shields, MD;
Jacqueline Cater, PhD;
Kaan Gündüz, MD;
Curtis Miyamoto, MD;
Bizhan Micaily, MD;
Luther W. Brady, MD
Arch Ophthalmol. 2000;118:1219-1228.
Objective To identify clinical predictive factors for visual outcome in a large series of patients who underwent plaque radiotherapy for uveal melanoma.
Design Clinical factors, including patient data, tumor features, and radiation variables, were analyzed for their impact on visual acuity using Cox proportional hazards regression models.
Participants Patients with uveal melanoma and initial visual acuity of 20/100 or better in the affected eye who were treated with plaque radiotherapy between July 1976 and June 1992.
Main Outcome Measures Two end points were used to evaluate posttreatment visual acuity: (1) final visual acuity (good [20/20-20/100] vs poor [20/200 to no light perception]) and (2) loss of visual acuity (minimal [<5 lines Snellen visual acuity] vs moderate [ 5 lines Snellen visual acuity]).
Results Of 1300 consecutive patients with uveal melanoma treated by plaque radiotherapy, 1106 had a visual acuity of 20/100 or better at the time of treatment. In this group, poor visual acuity was found in 34% at 5 years and 68% at 10 years of follow-up. From multivariable analysis, clinical factors that best predicted poor visual acuity were increasing tumor thickness, proximity to foveola of less than 5 mm, notched plaque shape, tumor recurrence, patient age 60 years or older, subretinal fluid, cobalt isotope, anterior tumor margin posterior to equator, and worse initial visual acuity. Moderate loss of visual acuity of 5 Snellen lines or more was found in 33% at 5 years and 69% at 10 years of follow-up. From multivariable analysis, clinical factors that best predicted moderate visual acuity loss included increasing tumor thickness, worse initial visual acuity, notched plaque shape, tumor recurrence, proximity to foveola of less than 5 mm, patient age of 60 years or older, subretinal fluid, and diabetes mellitus or hypertension. When analyzing visual outcome with regard to tumor thickness, ultimate poor visual acuity of 20/200 or worse at 5 years was found in 24% with a small melanoma ( 3.0 mm), 30% with a medium melanoma (3.1-8.0 mm), and 64% with a large melanoma (>8.0 mm). When analyzing visual outcome with regard to tumor proximity to visually important structures, tumors less than 5 mm from the optic disc or foveola demonstrated poor visual acuity in 35% at 5 years, whereas those 5 mm or more from the optic disc and foveola showed poor visual acuity in 25% at 5 years.
Conclusions Ultimate visual acuity after plaque radiotherapy for uveal melanoma depends on many factors, including patient age and general health, initial visual acuity, tumor location and size, subretinal fluid, radioactive isotope, and final tumor control. At 10 years' follow-up, 68% of patients demonstrate poor visual acuity. Visual acuity is most effectively preserved in eyes with small tumors outside a radius of 5 mm from the optic disc and foveola.
From the Oncology Service, Wills Eye Hospital, Thomas Jefferson University (Drs C. L. Shields, J. A. Shields, Cater, and Gündüz), and the Department of Radiation Oncology, MCP Hahnemann University (Drs Miyamoto, Micaily, and Brady), Philadelphia, Pa.
RELATED ARTICLE
Archives of Ophthalmology Reader's Choice: Continuing Medical Education
Arch Ophthalmol. 2000;118(9):1310-1311.
FULL TEXT
THIS ARTICLE HAS BEEN CITED BY OTHER ARTICLES
|
Posterior uveal melanoma. Distribution of the sites of origin and patterns of tumour extent in the ocular fundus
Krohn et al.
Br. J. Ophthalmol. 2008;92:751-756.
ABSTRACT
| FULL TEXT
Measurement of Human Choroidal Melanoma Xenograft Volume in Rats Using High-Frequency Ultrasound
Braun and Vistisen
IOVS 2008;49:16-22.
ABSTRACT
| FULL TEXT
Plaque Radiotherapy for Choroidal Melanoma Encircling the Optic Disc (Circumpapillary Choroidal Melanoma)
Sagoo et al.
Arch Ophthalmol 2007;125:1202-1209.
ABSTRACT
| FULL TEXT
Manganese-Enhanced MRI of Human Choroidal Melanoma Xenografts
Braun et al.
IOVS 2007;48:963-967.
ABSTRACT
| FULL TEXT
18 Years' experience with high dose rate strontium-90 brachytherapy of small to medium sized posterior uveal melanoma
van Ginderdeuren et al.
Br. J. Ophthalmol. 2005;89:1306-1310.
ABSTRACT
| FULL TEXT
Functional Analysis of the p53 Pathway in Response to Ionizing Radiation in Uveal Melanoma
Sun et al.
IOVS 2005;46:1561-1564.
ABSTRACT
| FULL TEXT
Combined plaque radiotherapy and transpupillary thermotherapy in choroidal melanoma: 5 years' experience
Bartlema et al.
Br. J. Ophthalmol. 2003;87:1370-1373.
ABSTRACT
| FULL TEXT
Ocular Melanoma: A Review and the Relationship to Cutaneous Melanoma
Hurst et al.
Arch Dermatol 2003;139:1067-1073.
ABSTRACT
| FULL TEXT
Transscleral Thermotherapy: Short- and Long-term Effects of Transscleral Conductive Heating in Rabbit Eyes
Rem et al.
Arch Ophthalmol 2003;121:510-516.
ABSTRACT
| FULL TEXT
Evidence-Based Estimates of Outcome in Patients Irradiated for Intraocular Melanoma
Gragoudas et al.
Arch Ophthalmol 2002;120:1665-1671.
ABSTRACT
| FULL TEXT
Combined Plaque Radiotherapy and Transpupillary Thermotherapy for Choroidal Melanoma: Tumor Control and Treatment Complications in 270 Consecutive Patients
Shields et al.
Arch Ophthalmol 2002;120:933-940.
ABSTRACT
| FULL TEXT
|
